A prospective study of efficacy and safety of lenvatinib in patients with RAI-refractory differentiated thyroid cancer patients

A prospective study of efficacy and safety of lenvatinib in patients with RAI-refractory differentiated thyroid cancer patients - Liberty-study (Efficacy and benefit of lenvatinib after resistance to I-131 treatment for differentiated thyroid cancer)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021757

Enrollment

320

Registered

2016-04-03

Start date

2016-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

Daily 20mg of lenvatinib is orally administered until tumor progression or the onset of untolerable adverse events.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with I-131-resistant differentiated thyroid cancer a) unresectable b) pathologically proven PTC or FTC c) measurable lesions acccording to RECIST1.1 criteria d) RAI-resistance e) no (or controled) brain metastases f) controled blood pressure g) Patients with sufficient organ function h) low THS i) Performance status (ECOG) of 0-2 j) Written informed concent

Exclusion criteria

Exclusion criteria: a) undifferentiated and medullary carcinoma b) prior therapy with lenvatinib c) preteninuria d) with severe heart failure e) bleeding/atherothrombotic disorder, or use of anticoagulants f) with another active malignant tumors g) pregnant and/or lactating women h) judged to be unfit to this study by investigater

Design outcomes

Primary

Measure	Time frame
progression-free survival	—

Countries

Japan

Contacts

Public ContactAOKI Shuri

The University of Tokyo Hospital Department of Radiology

daisy.shuri@gmail.com+81-3-5800-8667

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026